Leave a Reply

2388 Comments on "Comments"

Notify of
Sort by:   newest | oldest | most voted
baz22
Member

La jolla kept popping up here and there… kept thinking back to baby Regeneron… mabe it doesn’t take 200 employees to really get it right.. http://medicinova.com/clinical-development/development-pipeline/…. anyway, scaling back on crspr stocks untill clinical results start… seems everybody and their uncle are doing car-t…

indyrjc
Member
Reply to earlier post: “Rush, rush. Then have to deal with the law of unintended consequences. All in the name of trying to look good. “Fail to plan, plan to fail.” This is not good leadership.” There hasn’t been any true leadership in the United States for decades. Every member of every party is beholden to one group or another. As for poor leadership nothing beats the “Affordable Care Act”. Over half of those on subsidized policies now default on their out of pocket deductibles which is a big part of why insurance companies are bailing out one after another.… Read more »
baz22
Member

Thank you Bill… committed. *** also, will let ‘ blcm ‘ slide untill sometime next year/ or first strong leg past $ 10.50’s… downward pressure is to great at this time…

baz22
Member

Crispr landscape.. https://www.ipstudies.ch/crispr-patent-analytics/ … notice that the first four ( longest ) blue lines are Editas ( EDIT ) and Intellia ( NTLA ) parent/founders… > https://www.broadinstitute.org/news/broad-institute-harvard-and-mit-license-crispr-cas9-technology-editas-medicine-therapeutic

baz22
Member
swing_trader
Member
The Trump-directed tax cut plan is going to be bad for the country (U.S.) in the long term. The corporate tax cut benefits will mostly go to the shareholders’ and CEOs’ pockets through stock buy-backs and dividends. This is fine in the short term, but what is really needed for the U.S. economy growth to not fizzle out within a few years is to put the money into the pockets of the middle class so they can buy more goods. The investors’ profits will not ‘trickle down’ to the middle class. The only hope for the long term is corporations… Read more »
swing_trader
Member
The encouraging investment environment for U.S. citizens and companies into Cuba is pretty much on hold given Trump’s latest actions with regard to Cuba. “Starting Thursday (Nov. 9, 2017), U.S. tourists and companies will no longer be able to do business with a long list of entities that allegedly have ties to Cuban military, intelligence or security services.” Travel to Cuba will be restricted for U.S. citizens. “American tourists will also no longer be able to travel to Cuba on individual people-to-people exchange programs. They must travel now with a sponsoring organization or, if there on educational travel, with an… Read more »
baz22
Member

Hi Bill… tough one to plot… the latest trial readouts were really good, as a different metric was used from prior disappointing reads of a couple of years ago.. They had the reverse split few years back and then the share sales that chopped it almost in half.from the $ 6.00’s.. Phase 2 will take it into late 2018… could move fast… thinking Randall will let things evolve for awhile before talks, as he has substantial dollars involved… https://seekingalpha.com/article/4034477-sophiris-bio-future-biotech-blockbuster-just-internet-memes?page=2

wpDiscuz

Disclaimer: billcara.com is a website published by Greenfield Capital Inc and neither Greenfield Capital nor billcara.com is a registered broker-dealer or a registered investment adviser. You understand that this web site and its content is furnished for non-commercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold that or any other security, nor any particular portfolio of securities, transaction or investment strategy as suitable for any specific person. Information regarding trading and investment as provided by this website is not tailored to the investment needs of any specific person. Greenfield Capital and billcara.com services will not advise you personally concerning the nature, potential, value or suitability of any particular security, securities portfolio, transaction or other matter. You acknowledge that you are responsible for your own financial decisions and should seek a registered agent depending on your own risk tolerance to advise you on your personal trading activities.